Protagonist Therapeutics Profit Margin 2015-2021 | PTGX
Current and historical gross margin, operating margin and net profit margin for Protagonist Therapeutics (PTGX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Protagonist Therapeutics net profit margin as of June 30, 2021 is -299.39%.
|Protagonist Therapeutics Annual Profit Margins
|Protagonist Therapeutics Quarterly Profit Margins
||Medical - Biomedical and Genetics
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.